Skip to contentM
Mangoceuticals, Inc.
M
MGRXMangoceuticals, Inc. Q2 2026 · 10-Q
Revenue$68.76K$68.76K−59.1% vs Q2 2025 Net Income-$1.31M-$1.31MN/M vs Q2 2025 EPS Diluted-$0.09-$0.09N/M vs Q2 2025 Gross Profit$44,215−50.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Mangoceuticals, Inc. · CIK 1938046 · Engraved from SEC EDGAR
Operating Cash Flowderived-$260,506N/M Margins · derivedGross margin64.3%+10.8 pt vs Q2 2025
Operating margin-1502.5%+1631.5 pt vs Q2 2025
Net margin-1909.1%+1312.5 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end